Comparison of outcome measures before treatment, after six weeks and after 52 weeks of treatment with infliximab in patients with severe AS
| Variables | Week 0 | Week 6 | Week 52 |
|---|---|---|---|
| The numbers in parentheses indicate the standard deviation. | |||
| BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Disease Functional Index; GAP, global assessment of pain; VAS, visual analogue scale; CRP, C reactive protein; ESR, erythrocyte sedimentation rate. | |||
| *p<0.05; **p<0.01; ***p<0.001. | |||
| BASDAI | 57.7 (19.7) | 32.5 (19.5)*** | 15.4 (16.1)*** |
| BASFI | 58.3 (22.2) | 33.3 (16.2)*** | 16.3 (14.0)*** |
| Patient’s GAP (100 mm VAS) | 65.3 (16.7) | 20.1 (18.6)*** | 20.4 (13.4) |
| Patient’s global assessment of disease activity (100 mm VAS) | 54.1 (18.9) | 29.2 (16.4)*** | 20.8 (12.3)* |
| Doctor’s global assessment of disease activity (100 mm VAS) | 49.3 (15.5) | 26.3 (10.5)*** | 20.5 (10.0)* |
| Schober test (cm) | 1.8 (1.6) | 2.2 (1.6)* | 2.1 (1.4) |
| Chest expansion (cm) | 1.8 (0.8) | 2.3 (1.3) | 2.3 (1.3) |
| Weight (kg) | 74.4 (10.2) | 75.5 (9.8)** | 78.3 (9.6)** |
| CRP (mg/l) | 27.1 (21.0) | 1.9 (3.4)*** | 7.5 (13.5) |
| ESR (mm/1st h) | 33.9 (19.1) | 8.0 (5.9)*** | 15.8 (21.6) |